{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:59:15Z","timestamp":1769108355680,"version":"3.49.0"},"publisher-location":"Chichester, UK","reference-count":125,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003725.pub3","type":"reference-entry","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T01:11:33Z","timestamp":1202260293000},"source":"Crossref","is-referenced-by-count":205,"title":["Glucocorticoid corticosteroids for Duchenne muscular dystrophy"],"prefix":"10.1002","author":[{"given":"Adnan Y","family":"Manzur","sequence":"first","affiliation":[]},{"given":"Thierry","family":"Kuntzer","sequence":"additional","affiliation":[]},{"given":"Mike","family":"Pike","sequence":"additional","affiliation":[]},{"given":"Anthony V","family":"Swan","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mus.880170405","article-title":"Deflazacort in Duchenne dystrophy: study of long-term effect","volume":"17","author":"Angelini","year":"1994","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0960-8966(94)00048-E","article-title":"Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy","volume":"5","author":"Backman","year":"1995","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archneur.62.1.128","article-title":"Intermittent Prednisone Therapy in Duchenne Muscular Dystrophy. A randomized controlled trial.","volume":"62","author":"Beenakker","year":"2005","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1991.00530160047012","article-title":"Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group","volume":"48","author":"Griggs","year":"1991","journal-title":"Archives of Neurology"},{"issue":"24","key":"10.1002\/14651858.CD003725.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB6|cit6","first-page":"38","article-title":"Prednisolone in Duchenne muscular dystrophy","volume":"27","author":"Rahman","year":"2001","journal-title":"Bangladesh Medical Research Council Bulletin"},{"key":"10.1002\/14651858.CD003725.pub3-BIB7|cit7","first-page":"615","article-title":"Low-dosage prednisolone in the long-term treatment of Duchenne muscular dystrophy","volume":"13","author":"Ahlander","year":"2003","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD003725.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2106\/00004623-200403000-00009","article-title":"Steroid Treatment and the Development of Scoliosis in Males with Duchenne Muscular Dystrophy","volume":"86A(3)","author":"Alman","year":"2004","journal-title":"Journal of Bone and Joint Surgery American volume"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003725.pub3-BIB9|cit9","first-page":"A182","article-title":"Daily versus alternate-day deflazacort (DFZ) in Duchenne muscular dystrophy","volume":"45","author":"Angelini","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mus.20812","article-title":"The role of corticosteroids in muscular dystrophy: A critical appraisal","volume":"36","author":"Angelini","year":"2007","journal-title":"Muscle and Nerve"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB11|cit11","first-page":"187","article-title":"Steroid treatment in Duchenne's muscular dystrophy","volume":"53","author":"Aviles","year":"1982","journal-title":"Revista Chilena de Pediatra"},{"key":"10.1002\/14651858.CD003725.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/01.phm.0000184156.98671.d0","article-title":"Corticosteroid treatment and Functional Improvement in Duchenne muscular dystrophy. Long-term effect","volume":"84","author":"Balaban","year":"2005","journal-title":"American Journal of Physical Medicine and Rehabilitation"},{"key":"10.1002\/14651858.CD003725.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1067\/mpd.2001.109601","article-title":"Deflazacort treatment of Duchenne muscular dystrophy","volume":"138","author":"Biggar","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"8-9","key":"10.1002\/14651858.CD003725.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.nmd.2004.05.001","article-title":"Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols","volume":"14","author":"Biggar","year":"2004","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromuscular Disorders"},{"issue":"9","key":"10.1002\/14651858.CD003725.pub3-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle & Nerve"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/jnnp.2005.078345","article-title":"The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy","volume":"77","author":"Bonifati","year":"2006","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/000992280304200408","article-title":"Vertebral fractures in boys with Duchenne muscular dystrophy","volume":"42","author":"Bothwell","year":"2003","journal-title":"Clinical Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archneur.1987.00520200016010","article-title":"Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone","volume":"44","author":"Brooke","year":"1987","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB20|cit20","first-page":"A476","article-title":"A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity","volume":"46","author":"Brooke","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB21|cit21","doi-asserted-by":"crossref","unstructured":"Campbell C Jacob P Deflazacort for the treatment of Duchenne Dystrophy: a systematic review BMC Neurology 2003 7","DOI":"10.1186\/1471-2377-3-7"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0960-8966(02)00180-3","article-title":"High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy","volume":"12","author":"Connolly","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1542\/peds.2006-1400","article-title":"Effect of long-term steroids in cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy","volume":"119","author":"Daftary","year":"2007","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD003725.pub3-BIB24|cit24","first-page":"737","article-title":"The effectiveness of prednisolone treatment (10 days on \/10 days off) in the ambulatory phase of Duchenne muscular dystrophy: an open study","volume":"12","author":"Groot","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/archneur.1987.00520200022012","article-title":"Prednisone treatment in Duchenne muscular dystrophy","volume":"44","author":"DeSilva","year":"1987","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","article-title":"Prednisone in Duchenne muscular dystrophy","volume":"14","author":"Drachman","year":"1974","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/ejpn.2002.0583","article-title":"Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy","volume":"6","author":"Dubowitz","year":"2002","journal-title":"European Journal of Paediatric Neurology"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB28|cit28","first-page":"A544","article-title":"Deflazacort treatment and respiratory function in Duchenne muscular dystrophy","volume":"52 Suppl","author":"Dubrovsky","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archneur.1991.00530180027012","article-title":"A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy","volume":"48","author":"Fenichel","year":"1991","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1212\/WNL.41.12.1874","article-title":"Long-term benefit from prednisolone in Duchenne muscular dystrophy","volume":"41","author":"Fenichel","year":"1991","journal-title":"Neurology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD003725.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.43.3_Part_1.520","article-title":"Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)","volume":"43","author":"Griggs","year":"1993","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003725.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0960-8966(02)00097-4","article-title":"An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy","volume":"12","author":"Kinali","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpn.2006.12.002","article-title":"Predictive factors for the development of scoliosis in Duchenne muscular dystrophy","volume":"11","author":"Kinali","year":"2007","journal-title":"European Journal of Paediatric Neurology"},{"issue":"19","key":"10.1002\/14651858.CD003725.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily dose corticosteroid treatment in Duchenne Muscular Dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","article-title":"Steroid therapy and cardiac function in Duchenne muscular dystrophy","volume":"26","author":"Markham","year":"2005","journal-title":"Pediatric Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.10319","article-title":"Early prednisone treatment in Duchenne muscular dystrophy","volume":"27","author":"Merlini","year":"2003","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0960-8966(91)90099-E","article-title":"Steroids in Duchenne muscular dystrophy - deflazacort trial","volume":"1","author":"Mesa","year":"1991","journal-title":"Neuromuscular Disorders"},{"issue":"6,7","key":"10.1002\/14651858.CD003725.pub3-BIB38|cit38","first-page":"630","article-title":"Effect of daily prednisone on independent ambulation in patients with Duchenne dystrophy treated for up to 15 years","volume":"11","author":"Pandya","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"2A","key":"10.1002\/14651858.CD003725.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1590\/S0004-282X2007000200011","article-title":"Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy","volume":"65","author":"Parreira","year":"2007","journal-title":"Arquivos de Neuro-Psiquiatria"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00415-006-0212-1","article-title":"Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation","volume":"253","author":"Pradhan","year":"2006","journal-title":"Journal of Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD003725.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0387-7604(95)00015-1","article-title":"Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study","volume":"17","author":"Reitter","year":"1995","journal-title":"Brain & Development"},{"key":"10.1002\/14651858.CD003725.pub3-BIB42|cit42","first-page":"630","article-title":"Deflazacort in Duchenne muscular dystrophy: preliminary results in a Brazilian series","volume":"11","author":"Resende","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"5-6","key":"10.1002\/14651858.CD003725.pub3-BIB43|cit43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0960-8966(93)90117-3","article-title":"Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule","volume":"3","author":"Sansome","year":"1993","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00131402-200106000-00002","article-title":"Long-term steroid therapy in Duchenne Muscular Dystrophy-Positive results versus side effects","volume":"2","author":"Schara","year":"2001","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB45|cit45","first-page":"32","article-title":"Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study","volume":"145","author":"Siegel","year":"1974","journal-title":"Illinois Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0002-9149(02)03429-X","article-title":"Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy","volume":"91","author":"Silversides","year":"2003","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB47|cit47","first-page":"72","article-title":"High dose (2 mg\/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy","volume":"7 Suppl","author":"Todorovic","year":"1998","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD003725.pub3-BIB48|cit48","first-page":"630","article-title":"Alternate day prednisone therapy in Duchenne muscular dystrophy","volume":"11","author":"Tunca","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB49|cit49","first-page":"20","article-title":"Duchenne muscular dystrophy: therapeutic options and rehabilitation","volume":"3 Suppl","author":"Vasanth","year":"1996","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB50|cit50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/088307380201700306","article-title":"Corticosteroids in Duchenne muscular dystrophy: a reappraisal","volume":"17","author":"Wong","year":"2002","journal-title":"Journal of Child Neurology"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub3-BIB51|cit51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1468-1331.2004.00866.x","article-title":"Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis","volume":"11","author":"Yilmaz","year":"2004","journal-title":"Europeon Journal of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD003725.pub3-BIB52|cit52","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archneur.1981.00510070040004","article-title":"Loss of strength and functional decline in Duchenne dystrophy","volume":"38","author":"Allsop","year":"1981","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/096368970000900411","article-title":"Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy","volume":"9","author":"Anderson","year":"2000","journal-title":"Cell Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410160206","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells","volume":"16","author":"Arahata","year":"1984","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB55|cit55","volume-title":"Steroid therapy","author":"Azarnoff","year":"1975"},{"key":"10.1002\/14651858.CD003725.pub3-BIB56|cit56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jcp.1041020105","article-title":"A synergistic effect of glucocorticosteroids and insulin on the differentiation of myoblasts","volume":"102","author":"Bal","year":"1980","journal-title":"Journal of Cell Physiology"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0960-8966(01)00193-6","article-title":"Reference values of maximum isometric muscle force obtained in 270 children aged 4 -16 years by hand-held dynamometry","volume":"11","author":"Beenakker","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB58|cit58","doi-asserted-by":"crossref","first-page":"387-93","DOI":"10.1016\/j.ejpn.2005.06.004","article-title":"Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients","volume":"9","author":"Beenakker","year":"2005","journal-title":"European Journal of Paediatric Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nmd.2004.09.010","article-title":"Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004","volume":"15","author":"Biggar","year":"2005","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD003725.pub3-BIB60|cit60","volume-title":"British National Formulary","volume":"52","year":"2006"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB61|cit61","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/mus.880040304","article-title":"Clinical trial in Duchenne dystrophy. I. The design of the protocol","volume":"4","author":"Brooke","year":"1981","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mus.880060204","article-title":"Clinical investigation in Duchenne dystrophy. 2. Determination of the 'power' of therapeutic trials based on natural history","volume":"6","author":"Brooke","year":"1983","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0960-8966(02)00213-4","article-title":"107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands","volume":"13","author":"Bushby","year":"2003","journal-title":"Neuromuscular Disorders"},{"issue":"8-9","key":"10.1002\/14651858.CD003725.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.nmd.2004.05.006","article-title":"Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands","volume":"14","author":"Bushby","year":"2004","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB65|cit65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.nmd.2007.01.006","article-title":"145th ENMC International Workshop: Planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD). 22-24th October 2006, Naarden, The Netherlands","volume":"17","author":"K","year":"2007","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD003725.pub3-BIB66|cit66","unstructured":"Clarke M Oxman AD Assessment of study quality Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]; Section 6; In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of Duchenne muscular dystrophy: Current hypotheses","volume":"36","author":"Deconinck","year":"2007","journal-title":"Pediatric Neurology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB68|cit68","volume-title":"Muscle Disorders in Childhood","author":"Dubowitz","year":"1978"},{"key":"10.1002\/14651858.CD003725.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/oxfordjournals.bmb.a071629","article-title":"Management of muscular dystrophy: pharmacological and physical aspects","volume":"36","author":"Dubowitz","year":"1980","journal-title":"British Medical Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB70|cit70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0960-8966(91)90019-O","article-title":"Prednisone in Duchenne dystrophy","volume":"1","author":"Dubowitz","year":"1991","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD003725.pub3-BIB71|cit71","volume-title":"Muscle Disorders in Childhood","author":"Dubowitz","year":"1995"},{"key":"10.1002\/14651858.CD003725.pub3-BIB72|cit72","first-page":"261","article-title":"47th European Neuromuscular Centre International workshop: treatment of muscular dystrophy. 13-15 December,1996, Naarden, The Netherlands","volume":"7","author":"Dubowitz","year":"1997","journal-title":"Neuromuscular Disorders"},{"issue":"4-5","key":"10.1002\/14651858.CD003725.pub3-BIB73|cit73","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0960-8966(00)00126-7","article-title":"75th European Neuromuscular Centre International workshop: 2nd workshop on the treatment of muscular dystrophy, 10-12 December, 1999, Naarden, The Netherlands","volume":"10","author":"Dubowitz","year":"2000","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB74|cit74","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(05)70050-8","article-title":"Prednisone for Duchenne Muscular Dystrophy","volume":"4","author":"Dubowitz","year":"2005","journal-title":"The Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0960-8966(98)00047-9","article-title":"Steroids in muscular dystrophy: Where do we stand?","volume":"8","author":"Dubrovsky","year":"1998","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB76|cit76","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.2353\/ajpath.2006.050683","article-title":"Sarcolemmal Damage in Dystrophin Deficiency Is Modulated by Synergistic Interactions between Mechanical and Oxidative\/Nitrosative Stresses","volume":"168","author":"Dudley","year":"2006","journal-title":"American Journal of Pathology"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub3-BIB77|cit77","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB78|cit78","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.nmd.2007.03.002","article-title":"Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival","volume":"17","author":"Eagle","year":"2007","journal-title":"Neuromuscular Disorders"},{"issue":"6261","key":"10.1002\/14651858.CD003725.pub3-BIB79|cit79","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bmj.282.6261.351","article-title":"Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown","volume":"282","author":"Elia","year":"1981","journal-title":"British Medical Journal (Clinical Research Ed)"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB80|cit80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases: a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD003725.pub3-BIB81|cit81","volume-title":"Diagnostic Criteria for Neuromuscular Disorders","author":"Emery","year":"1997"},{"key":"10.1002\/14651858.CD003725.pub3-BIB82|cit82","article-title":"Duchenne muscular dystrophy","volume-title":"Oxford Monographs on Medical Genetics","author":"Emery","year":"2003"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB83|cit83","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.410120314","article-title":"Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers","volume":"12","author":"Engel","year":"1982","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB84|cit84","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0046-8177(76)80053-6","article-title":"The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis","volume":"7","author":"Frankel","year":"1976","journal-title":"Human Pathology"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB85|cit85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2165\/00003088-199019020-00003","article-title":"Clinical pharmacokinetics of prednisone and prednisolone","volume":"19","author":"Frey","year":"1990","journal-title":"Clinical Pharmacokinetics"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB86|cit86","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/oxfordjournals.bmb.a071623","article-title":"Clinical features and classification of the muscular dystrophies","volume":"36","author":"Gardner-Medwin","year":"1980","journal-title":"British Medical Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB87|cit87","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00002060-200206000-00003","article-title":"Duchenne muscular dystrophy: prolongation of life by noninvasive ventilation and mechanically assisted coughing","volume":"81","author":"Gomez-Merino","year":"2002","journal-title":"American Journal of Physical and Medical Rehabilitation"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB88|cit88","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1469-8749.1985.tb03763.x","article-title":"Prolongation of walking in Duchenne Muscular Dystrophy with lightweight orthoses; review of 57 cases","volume":"27","author":"Heckmatt","year":"1985","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB89|cit89","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/oxfordjournals.bmb.a072358","article-title":"Management of children: pharmacological and physical","volume":"45","author":"Heckmatt","year":"1989","journal-title":"British Medical Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB90|cit90","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB91|cit91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11940-001-0045-2","article-title":"Duchenne muscular dystrophy","volume":"3","author":"Iannaccone","year":"2001","journal-title":"Current Treatment Options in Neurology"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB92|cit92","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00002060-199509000-00005","article-title":"A management trial for Duchenne cardiomyopathy","volume":"74","author":"Ishikawa","year":"1995","journal-title":"American Journal of Physical Medicine and Rehabilitation"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB93|cit93","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0002-8703(99)70414-X","article-title":"Cardioprotection for Duchenne's muscular dystrophy","volume":"137","author":"Ishikawa","year":"1999","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB94|cit94","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF00869001","article-title":"Prednisolone can protect against exercise-induced muscle damage","volume":"243","author":"Jacobs","year":"1996","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB95|cit95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub3-BIB96|cit96","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0960-8966(03)00162-7","article-title":"The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use","volume":"13","author":"Jeppesen","year":"2003","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB97|cit97","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1212\/WNL.41.5.667","article-title":"Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group","volume":"41","author":"Kissel","year":"1991","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB98|cit98","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion","volume":"45","author":"Koenig","year":"1989","journal-title":"American Journal of Human Genetics"},{"key":"10.1002\/14651858.CD003725.pub3-BIB99|cit99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/oso\/9780192632913.003.0012","article-title":"Medical management and treatment of muscular dystrophy","volume-title":"The muscular dystrophies","author":"Manzur","year":"2001"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB100|cit100","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003725.pub2","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","author":"Manzur","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB101|cit101","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0960-8966(93)90110-6","article-title":"The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies","volume":"3","author":"Matsumura","year":"1993","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB102|cit102","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mus.880170103","article-title":"Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies","volume":"17","author":"Matsumura","year":"1994","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB103|cit103","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/088307389501000219","article-title":"The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability","volume":"10","author":"Mendell","year":"1995","journal-title":"Journal of Child Neurology"},{"issue":"7","key":"10.1002\/14651858.CD003725.pub3-BIB104|cit104","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/j.1476-5381.1995.tb15930.x","article-title":"Modulation by prednisolone of calcium handling in skeletal muscle cells","volume":"116","author":"Metzinger","year":"1995","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB105|cit105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1212\/01.WNL.0000148485.00049.B7","article-title":"Practice Parameter: corticosteroid treatment of Duchenne dystrophy, report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society","volume":"64","author":"Moxley","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB106|cit106","volume-title":"Aids to the investigation of peripheral nerve injuries","year":"1976"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003725.pub3-BIB107|cit107","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/S0960-8966(02)00101-3","article-title":"Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research","volume":"12","author":"Muntoni","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub3-BIB108|cit108","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00019052-200310000-00003","article-title":"Cardiomyopathy in muscular dystrophies","volume":"16","author":"Muntoni","year":"2003","journal-title":"Current Opinion in Neurology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB109|cit109","series-title":"Neuromuscular Disorders","first-page":"210-9","article-title":"Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London, UK","author":"Muntoni","year":"2006"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub3-BIB110|cit110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/hmg\/ddg065","article-title":"cDNA microarray analysis of individual Duchenne muscular dystrophy patients","volume":"12","author":"Noguchi","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB111|cit111","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0960-8966(94)00042-8","article-title":"The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells","volume":"5","author":"Pasquini","year":"1995","journal-title":"Neuromuscular Disorders"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub3-BIB112|cit112","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.bjp.0702036","article-title":"Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells","volume":"124","author":"Passaquin","year":"1998","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB113|cit113","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1096\/fj.06-7285com","article-title":"Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression","volume":"21","author":"Pescatori","year":"2007","journal-title":"The FASEB Journal"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub3-BIB114|cit114","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proceedings of the National Academy of Sciences, USA"},{"issue":"1-2","key":"10.1002\/14651858.CD003725.pub3-BIB115|cit115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1006812004945","article-title":"The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy","volume":"179","author":"Petrof","year":"1998","journal-title":"Molecular Cell Biochemistry"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB116|cit116","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/hmg\/11.3.263","article-title":"A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice","volume":"11","author":"Porter","year":"2002","journal-title":"Human Molecular Genetics"},{"issue":"15","key":"10.1002\/14651858.CD003725.pub3-BIB117|cit117","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/hmg\/ddg197","article-title":"Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice","volume":"12","author":"Porter","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub3-BIB118|cit118","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nmd.2004.09.009","article-title":"Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004","volume":"15","author":"Quinlivan","year":"2005","journal-title":"Neuromuscular Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003725.pub3-BIB119|cit119","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/S0960-8966(02)00096-2","article-title":"Considerations to the policy of future clinical therapeutic trials in DMD","volume":"12","author":"Reitter","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"1 pt 1","key":"10.1002\/14651858.CD003725.pub3-BIB120|cit120","first-page":"E67","article-title":"Effect of prednisone on protein metabolism in Duchenne muscular dystrophy","volume":"268","author":"Rifai","year":"1995","journal-title":"American Journal of Physiology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB121|cit121","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/088307388800300407","article-title":"Prevention of rapidly progressive scoliosis in Duchenne muscular dystrophy by prolongation of walking with orthoses","volume":"3","author":"Rodillo","year":"1988","journal-title":"Journal of Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub3-BIB122|cit122","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.880050405","article-title":"Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy","volume":"5","author":"Scott","year":"1982","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub3-BIB123|cit123","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.43.3_Part_1.527","article-title":"Cyclosporine increases muscular force generation in Duchenne muscular dystrophy","volume":"43","author":"Sharma","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003725.pub3-BIB124|cit124","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2106\/00004623-196244020-00002","article-title":"Bracing for ambulation in childhood progressive muscular dystrophy","volume":"44A","author":"Spencer","year":"1962","journal-title":"Journal of Bone and Joint Surgery"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub3-BIB125|cit125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0304-3940(99)00418-8","article-title":"The effect of methylprednisone on intracellular calcium of normal and dystrophic human skeletal muscle cells","volume":"269","author":"Vandebrouck","year":"1999","journal-title":"Neuroscience Letters"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003725.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T00:00:00Z","timestamp":1462406400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003725.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T23:17:26Z","timestamp":1708557446000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003725.pub3"}},"subtitle":[],"editor":[{"given":"Adnan Y","family":"Manzur","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":125,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003725.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD003725.pub4","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2008,1,23]]}}}